- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03289650
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
Once-Daily Extended-Release Tacrolimus vs. Twice-Daily Tacrolimus: Impact on T-Cell Subpopulations and Markers of Renal Tubule-toxicity in Kidney Transplant Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. Lifelong immunosuppressive therapies are required to prevent organ rejection. However, long term exposure to immunosuppressive therapy after kidney transplantation can place patients at risk for multiple adverse events. The optimal immunosuppressive therapy is not well established. Tacrolimus, a calcineurin inhibitor (CNI) is highly effective in preventing acute rejection after organ transplantation (2). It is used as part of the immunosuppression regimen for the majority of kidney and liver transplant recipients (3). However, treatment with current formulation of Tacrolimus generates high peaks and low troughs in drug concentrations in the blood. It is known that high exposure to CNI is associated with renal toxicities and adverse events (4). New once-daily dosage formulations are now developed with the hope of minimizing side effects while maintaining excellent outcomes (5-8).
LCP-Tacro (Envarsus® XR, Veloxis Pharmaceuticals), a new once-daily formulation of tacrolimus, was approved by the FDA in 2015 for conversion from twice-daily tacrolimus in kidney transplant recipients. It is a prolonged-release tacrolimus formulation, utilizing a MeltDose drug delivery technology designed to improve the bioavailability of drugs with low water solubility (1). Recent clinical data demonstrated that once-daily LCP-Tacro has improved pharmacokinetic bioavailability, rapid achievement of therapeutic trough levels, less fluctuation and swing in whole blood concentration, non-inferior efficacy and similar safety, with lower tacrolimus dose than other tacrolimus formulations.
The target population is adult recipients of immediately functioning living and deceased donor renal allografts. Immediate function will be defined as the absence of the need for hemodialysis in the first week following renal transplantation.
Prospective randomized single center open label study of 2 groups of kidney transplant patients
- Group 1 : standard of care (SOC) control group will receive tacrolimus twice-daily (n=25)
- Group 2 : LCP-Tacro (Envarsus® XR) group will receive LCPT tablets once daily (n=25)
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Patients who are males or females aged 18-65 years. 2. Use of the following induction medications: basiliximab and rituximab. 2. Donors aged 18-65 years. 3. No prior organ transplant 4. Patients who are single-organ recipients (kidney only). 5. Women who are of childbearing potential must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of contraception throughout the treatment period.
6. Subject (recipient) is able to understand the consent form and give written informed consent
Exclusion Criteria:
- Delayed graft function (please see above).
- Known sensitivity or contraindication to alemtuzumab, Envarsus® XR, tacrolimus or MMF.
- Use of the following induction medications: basiliximab and rituximab
- Patient with significant or active infection.
- Patients with a positive flow cytometric crossmatch using donor lymphocytes and recipient serum.
- Patients with PRA > 40%
- Patients with current or historic donor specific antibodies
- Body Mass Index (BMI) of < 18 or > 35
- Patients who are pregnant or nursing mothers.
- Patients whose life expectancy is severely limited by diseases other than renal disease.
- Ongoing active substance abuse, drug or alcohol.
- Major ongoing psychiatric illness or recent history of noncompliance.
Significant cardiovascular disease (e.g.):
- Significant non-correctable coronary artery disease;
- Ejection fraction below 30%;
- History of recent myocardial infarction.
- Malignancy within 3 years, excluding non-melanoma skin cancers.
- Serologic evidence of infection with HIV or HBVs-Ag positive.
- Patients with a screening/baseline total white blood cell count < 4,000/mm3; platelet count < 100,000/mm3; triglyceride > 400 mg/dl; total cholesterol > 300 mg/dl.
- Investigational drug within 30 days prior to transplant surgery.
- Anti-T cell therapy within 30 days prior to transplant surgery.
- Diagnosis of atypical-Hemolytic Uremic Syndrome (aHUS).
- Subjects transplanted with a Hepatitis C NAT-positive kidney.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of care tacrolimus twice-daily
|
immunosuppressive agent tacrolimus, given twice-daily
|
Active Comparator: Extended-release tacrolimus once-daily
|
immunosuppressive agent extended-release tacrolimus, given once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant
Time Frame: 2 weeks post transplant through 12 months post transplant
|
change in the mean eGFR from the baseline (2 weeks post transplant), 3 months (post transplant) , and 12 months (post transplant).
|
2 weeks post transplant through 12 months post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Subpopulations of T Cells From 2 Weeks Post Transplant Through 12 Months Post Transplant
Time Frame: Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant
|
Blood, urine and kidney tissue analysis via serial flow cytometric immunophenotyping (includes regulatory T and B cell populations as well as immune functions).
|
Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant
|
Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant
Time Frame: Measured at 3 months post transplant, 12 months post transplant
|
Acute rejection of kidney transplant is determined via biopsy.
|
Measured at 3 months post transplant, 12 months post transplant
|
Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant
Time Frame: Measured at 3 months post transplant, 12 months post transplant
|
Graft loss is determined via biopsy.
|
Measured at 3 months post transplant, 12 months post transplant
|
Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant
Time Frame: Through 12 months post transplant
|
Subject survival status is continually monitored via routine follow-up visits.
|
Through 12 months post transplant
|
Number of Participants With Change in Allograft Immunohistopathology Profile
Time Frame: Measured at 3 months post transplant, 12 months post transplant
|
Tissue analysis via immunohistopathological staining and microscopic examination Moderate acute tubular necrosis => presence of focal coagulative necrosis or infarction on histopathologic examination Arteriolar hyalinosis grade 2 means: Replacement of degenerated smooth muscle cells by hyaline deposits in more than 1 arteriole, without circumferential involvement Global glomerulosclerosis >grade 2, means glomerulosclerosis affecting more than 50% of glomeruli in the biopsy sample IFTA : Interstitial fibrosis and tubular atrophy: Inflammation in 26% to 50% of scarred cortical parenchyma |
Measured at 3 months post transplant, 12 months post transplant
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00205327
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
Limerick BioPharmaCompleted
-
University of British ColumbiaPaladin Labs Inc.RecruitingLiver Transplantation | Neurotoxicity | Tremor | Tacrolimus | ImmunosuppressionCanada